NutraNomics Announces 2022 Topline Sales Expectations of $10.2M Based on Data from Current Operations and Upcoming Expansion in Active Product Lines

Rhea-AI Summary

NutraNomics, Inc. (OTC PINK:NNRX) provided a promising update on its financial performance for 2022. Sales for the first four months reached $1.09 million, marking a 217% year-over-year increase. Management projects monthly sales to grow by 25% month-over-month, aiming for a total of approximately $10.2 million for the year, driven by new product releases and existing sales growth.

CEO Jonathan Bishop highlighted 60% sequential growth potential for Q2, boosted by the new 'Red Eye' product line and additional branded products scheduled for release.

Positive

• Sales growth of 217% year-over-year during the first four months of 2022.
• Projected total sales of approximately $10.2 million for 2022.
• Expected monthly sales increase of 25% month-over-month through year-end.
• CEO indicates 60% sequential quarterly growth for Q2 based on current trends.

Negative

• None.

DESERT HOT SPRINGS, CA / ACCESSWIRE / June 23, 2022 / NutraNomics, Inc. (OTC PINK:NNRX) ("NutraNomics" or the "Company"), an emerging leader in organic plant-based nutritional science and innovation, is pleased to provide current and prospective shareholders with an update on the Company's topline performance and 2022 expectations as Q2 winds down following the closing of the Company's recent acquisition of DHS Development, Inc. (dba "The Plant").

Sales during the first four calendar months of 2022 closed at $1.09 million, representative of a strong year-to-date year-over-year revenue increase of 217% when compared to the same period in 2021.

Based on that data, along with relevant broad market forecasts and planned upcoming new product releases, management anticipates a steady increase in monthly topline sales performance by roughly 25% month-over-month through year end, driving a total of approximately $10.2 million in 2022 sales from related products.

This forecast includes sequential monthly growth data from existing products year-to-date as well as anticipated key new product releases.

"We have enough insight into the market and the performance we are seeing from our recent acquisition to make some forecasts through year end, with the data being driven by sales of Bulk Concentrates, Contract Manufacturing, Co-Packing, Pre-rolls, and Gummies," remarked Jonathan Bishop, CEO of NutraNomics. "Those operating divisions are now active and reflected in year-to-date sales data."

Bishop added, "If we line up Q1 data against what we have seen in just the first 7 weeks of Q2, we are on pace for approximately 60% sequential quarterly growth. But that doesn't include our recent release of The Plant's Branded ‘Red Eye' product line, and the anticipated formulation and release of several branded products set to hit the market throughout the remainder of the year."

About NutraNomics
At NutraNomics, Inc. (OTC PINK:NNRX), we are committed to excellence in organic plant-based nutritional science and innovation. That was our stance when we began in 1996, and it is still our stance today.

NutraNomics Website: https://www.nutranomics.com

NutraNomics Twitter: https://www.twitter.com/nutranomicsinc

Forward-Looking Statements
Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update the information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

Press Contact:
Geoff Bazegian, IR@nutranomics.com

Public Relations
EDM Media, LLC
https://edm.media

SOURCE: NutraNomics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/706273/NutraNomics-Announces-2022-Topline-Sales-Expectations-of-102M-Based-on-Data-from-Current-Operations-and-Upcoming-Expansion-in-Active-Product-Lines

FAQ

What are NutraNomics' sales figures for 2022 (NNRX)?

NutraNomics reported $1.09 million in sales for the first four months of 2022, with a projection of approximately $10.2 million for the entire year.

What is the expected sales growth for NutraNomics (NNRX) in 2022?

Management anticipates a monthly sales increase of about 25% month-over-month through the end of 2022.

How much did NutraNomics' sales increase year-over-year (NNRX)?

NutraNomics experienced a 217% year-over-year increase in sales during the first four months of 2022.

What is the significance of the 'Red Eye' product line for NutraNomics (NNRX)?

The 'Red Eye' product line is expected to contribute to NutraNomics' sales growth and form part of their strategy for expanding market presence.

What does CEO Jonathan Bishop say about Q2 sales expectations for NutraNomics (NNRX)?

CEO Jonathan Bishop indicated that NutraNomics is on pace for approximately 60% sequential growth for Q2 based on sales performance.